Segment Reporting (Tables)
|
6 Months Ended |
Jun. 30, 2026 |
|---|
| Segment Reporting |
|
| Schedule of financial information by reporting segment |
| | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | | | (in thousands) | Net revenues: | | $ | 183,903 | | $ | 174,414 | | $ | 355,074 | | $ | 344,942 | Less: | | | | | | | | | | | | | Payroll expense | | | 51,122 | | | 48,052 | | | 101,740 | | | 97,362 | Materials and supplies | | | 10,500 | | | 11,217 | | | 23,241 | | | 21,696 | Clinical trials expense | | | 3,524 | | | 189 | | | 5,076 | | | 1,137 | Depreciation and amortization expense | | | 14,311 | | | 14,616 | | | 28,659 | | | 28,225 | Stock-based compensation expense | | | 7,090 | | | 6,382 | | | 16,364 | | | 14,775 | Consulting and outside services expense | | | 11,033 | | | 8,265 | | | 21,395 | | | 17,850 | Advertising and promotional expense | | | 4,060 | | | 3,086 | | | 7,120 | | | 6,975 | Other segment items(1) | | | 39,347 | | | 38,912 | | | 94,358 | | | 78,168 | Interest income | | | (2,287) | | | (1,921) | | | (4,687) | | | (4,010) | Interest expense | | | 6,659 | | | 6,281 | | | 13,212 | | | 12,567 | Income tax provision | | | 8,196 | | | 8,305 | | | 11,828 | | | 13,882 | Net income | | $ | 30,348 | | $ | 31,030 | | $ | 36,768 | | $ | 56,315 |
|
| Schedule of net revenues in the finished pharmaceutical products segment |
| | | | | | | | | | | | | | | Three Months Ended | | Six Months Ended | | | June 30, | | June 30, | | | 2026 | | 2025 | | 2026 | | 2025 | | | | (in thousands) | Net revenues: | | | | | | | | | | | | | BAQSIMI® | | $ | 45,503 | | $ | 46,687 | | $ | 77,937 | | $ | 85,042 | Primatene MIST® | | | 21,004 | | | 22,880 | | | 50,767 | | | 51,931 | Epinephrine | | | 15,854 | | | 16,180 | | | 35,067 | | | 34,767 | Lidocaine | | | 15,039 | | | 14,999 | | | 28,499 | | | 28,643 | Glucagon | | | 11,905 | | | 20,602 | | | 21,075 | | | 41,445 | Ipratropium bromide | | | 8,411 | | | — | | | 8,411 | | | — | Other products | | | 66,187 | | | 53,066 | | | 133,318 | | | 103,114 | Total net revenues | | $ | 183,903 | | $ | 174,414 | | $ | 355,074 | | $ | 344,942 |
|
| Schedule of net revenues and carrying values of long-lived assets by geographic region |
| | | | | | | | | | | | | | | | | | | | | Net Revenues | | Long-Lived Assets | | | Three Months Ended | | Six Months Ended | | | | | | | | | June 30, | | June 30, | | June 30, | | December 31, | | | 2026 | | 2025 | | 2026 | | 2025 | | 2026 | | 2025 | | | | (in thousands) | United States | | $ | 172,342 | | $ | 167,002 | | $ | 331,382 | | $ | 329,592 | | $ | 247,218 | | $ | 206,697 | China | | | 4,560 | | | 299 | | | 7,042 | | | 380 | | | 107,268 | | | 110,055 | France | | | 7,001 | | | 7,113 | | | 16,650 | | | 14,970 | | | 34,640 | | | 36,967 | Total | | $ | 183,903 | | $ | 174,414 | | $ | 355,074 | | $ | 344,942 | | $ | 389,126 | | $ | 353,719 |
|